However exposure to PPARγ agonists during development can increase the number of fat cells produced during development, leading to an obese phenotype and development of metabolic syndrome in adults, marked by hyperinsulinemia, long after exposure to the PPARγ agonist has ceased40,102. This evidence concerns the gene PPARG and Hyperinsulinemia.